Abstract
Agrammatism is characterized by short sentences, the omission of function words, a higher ratio of heavy to light verbs, and a decreased use of verbs relative to nouns. Despite the observation of these phenomena more than two centuries ago, there has been no unifying theory to explain all features of agrammatism. Here, by first examining the language of patients with primary progressive aphasia, we show that the seemingly heterogeneous features of agrammatism can be explained by a process that selects lower frequency words over their higher frequency alternatives in the context of a limitation in sentence production, likely to increase the informational content of sentences. We further show that when healthy speakers are constrained to produce short sentences, features of agrammatism emerge in their language. Finally, we show that these findings instantiate a general property in healthy language production in which shorter sentences are constructed by selecting lower frequency words.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by NIH grants R01 DC014296, R01 DC013547, R21 DC019567, R21 AG073744, and by the Tommy Rickles Chair in Primary Progressive Aphasia Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB at Massachusetts General Hospital
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
